

Special Issue

Animal Vaccines

Message from the Guest Editors

Scientists have attempted to use different kinds of novel technologies in animal vaccine development. Since the regulatory requirements of clinical trials for animal products are shorter than those in human vaccines, novel technologies are easier to commercialize in animal vaccine products. Many bacterial and eukaryotic cell-expressed recombinant proteins and viral vectors have been used for decades, and many kinds of immune potentiating materials, such as peptides, proteins, polymers, and emulsified oils, have been used in adjuvants. Biosafety and high immunization efficacy are the basic requirements of a vaccine. However, easily immunizing operation and low manufacturing cost are also essential for a successful animal vaccine product. This Special Issue will not only include novel antigen or adjuvant design but also cover large-scale production and manufacturing improvement technologies.

Guest Editors

Dr. Hsian-Yu Wang

International Program in Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan

Prof. Dr. David Benfield

Department of Animal Sciences, The Ohio State University, Wooster Campus, 1680 Madison Avenue, Wooster, OH 44691, USA

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/114482

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).